window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-5QXBT1ZYW2'); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5GXNWGJ9'); function BannerImpression(a) { if (jQuery( window ).width() < '800'){ gtag('event', 'Impression', { 'event_category': a, 'event_label': 'Mobile'}); } else { gtag('event', 'Impression', { 'event_category': a, 'event_label': 'Desktop'}); } } function BannerClickW(a) { if (jQuery( window ).width() < '800'){ gtag('event', 'BannerClick', { 'event_category': a, 'event_label': 'Mobile'}); } else { gtag('event', 'BannerClick', { 'event_category': a, 'event_label': 'Desktop'}); } }
Diego Díaz García ASCO
Diego Díaz García/X

Diego A. Díaz García: Perioperative therapy is reshaping early-stage oncogene-driven NSCLC

Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare, shared a post on X about recent paper Teja Voruganti and colleagues authored:

“Perioperative therapy is reshaping early-stage oncogene-driven NSCLC.
EGFR+ disease has adjuvant osimertinib – but what about ALK, BRAF, KRAS?
Should TKIs replace or complement chemo-IO?
Molecular testing, MRD, and smarter sequencing are key. More answers coming soon.”
Perioperative therapy

Title: Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions

Journal: American Society of Clinical Oncology Educational Book

Authors: Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, and Charu Aggarwal

Read Full Article.

Diego A. Díaz García: Perioperative therapy is reshaping early-stage oncogene-driven NSCLC

More posts featuring NSCLC on OncoDaily.